- Home
- IMCR vs VRE Comparison
IMCR vs VRE Comparison
Compare IMCR & VRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- VRE
- Stock Information
- Founded
- IMCR 2008
- VRE 1949
- Country
- IMCR United Kingdom
- VRE United States
- Employees
- IMCR N/A
- VRE N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- VRE Real Estate Investment Trusts
- Sector
- IMCR Health Care
- VRE Real Estate
- Exchange
- IMCR Nasdaq
- VRE Nasdaq
- Market Cap
- IMCR 1.4B
- VRE 1.6B
- IPO Year
- IMCR 2021
- VRE 1994
- Fundamental
- Price
- IMCR $28.41
- VRE $15.88
- Analyst Decision
- IMCR Buy
- VRE Buy
- Analyst Count
- IMCR 12
- VRE 4
- Target Price
- IMCR $60.90
- VRE $18.75
- AVG Volume (30 Days)
- IMCR 403.7K
- VRE 618.0K
- Earning Date
- IMCR 05-07-2025
- VRE 04-23-2025
- Dividend Yield
- IMCR N/A
- VRE 1.83%
- EPS Growth
- IMCR N/A
- VRE N/A
- EPS
- IMCR N/A
- VRE N/A
- Revenue
- IMCR $310,202,000.00
- VRE $275,626,000.00
- Revenue This Year
- IMCR $20.52
- VRE $1.42
- Revenue Next Year
- IMCR $8.57
- VRE $1.39
- P/E Ratio
- IMCR N/A
- VRE N/A
- Revenue Growth
- IMCR 24.36
- VRE 4.40
- 52 Week Low
- IMCR $23.15
- VRE $13.84
- 52 Week High
- IMCR $62.74
- VRE $18.85
- Technical
- Relative Strength Index (RSI)
- IMCR 51.56
- VRE 49.63
- Support Level
- IMCR $26.37
- VRE $15.13
- Resistance Level
- IMCR $27.67
- VRE $15.46
- Average True Range (ATR)
- IMCR 1.76
- VRE 0.65
- MACD
- IMCR 0.10
- VRE -0.05
- Stochastic Oscillator
- IMCR 77.93
- VRE 57.52
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About VRE Veris Residential Inc.
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.